China Medical System Holdings Limited 2021 Interim Results Announcement prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Takeda organiza una conferencia telefónica sobre sus productos en desarrollo Wave 1
CAMBRIDGE, Mass. y OSAKA, Japón (BUSINESS WIRE)
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) ha anunciado hoy que realizará una conferencia telefónica el 6 de abril de 2021 para informar sobre las nuevas entidades moleculares (NEM) seleccionadas en su cartera de productos en desarrollo Wave 1. Con varias presentaciones de NEM ante las autoridades normativas previstas para fines del ejercicio fiscal 2021, la compañía mencionará sus planes para el crecimiento orgánico y sostenible de los ingresos durante los próximos años.
Texto completo a continuación
Takeda organiza una conferencia telefónica sobre sus productos en desarrollo Wave 1 - Iberonews iberonews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iberonews.com Daily Mail and Mail on Sunday newspapers.
9:00 p.m. – 9:05 p.m.
Introduction
8:05 a.m. – 8:10 a.m.
9:05 p.m. – 9:10 p.m.
Delivering an Innovative Pipeline to Our Patients: Spotlight on Select Wave 1 Programs
Andy Plump, president of Research and Development
8:10 a.m. – 8:35 a.m.
9:10 p.m. – 9:35 p.m.
Maribavir (TAK-620): Potential Game Changer in the Treatment for Post-Transplant Cytomegalovirus (CMV) Infection Obi Umeh, global program lead, Rare Genetic and Hematology Therapeutic Area Unit
Claus Jepsen, head of Global Product and Launch Strategy, Rare Genetic and Hematology Therapeutic Area Unit
8:35 a.m. – 8:40a.m.
9:35 p.m. – 9:40p.m.
Break
9:40 p.m. – 10:00 p.m.
Soticlestat (TAK-935): Novel MoA for Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome
Enveric Biosciences Issues Shareholder Letter Providing Strategic Vision for Advancing Novel Prescription Supportive Care Cancer Therapies
Advancing pipeline with naturally occurring and synthetic compounds initially focused on the development of cannabinoids for pharmaceutical use
Enveric has assembled a highly accomplished executive team, Board of Directors and Scientific Advisory Board to guide the Company through the regulatory and clinical pathway
Company evaluating business development opportunities for expanding IP portfolio and product pipeline to tackle new indications for additional treatments
News provided by
Share this article
NAPLES, Fla., Jan. 19, 2021 /PRNewswire/
Enveric Biosciences, Inc. (NASDAQ: ENVB) ( Enveric or the Company ), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today issued a shareholder letter from its Chairman and CEO, David Johnson, providing an update on the C